<?xml version="1.0" encoding="UTF-8"?>
<p>The model suggests expanded hepatitis B prevention and treatment for hepatitis B and C (using DAAs for the latter) is cost‐effective and affordable in the South African context,
 <xref rid="liv14222-bib-0035" ref-type="ref">35</xref> noting that hepatitis B birth dose vaccination should be prioritised if funds are insufficient for the full implementation. The five‐year Action Plan was estimated to cost US$270 million, with the “testing, care, and treatment” component being the most costly. Whilst this is a significant amount of money, seen against 5‐year HIV expenditure, the cost of the Hepatitis Action Plan is estimated to be less than 4% of the projected HIV spend in South Africa.
 <xref rid="liv14222-bib-0043" ref-type="ref">43</xref> Integrating the action plan into the existing health system, particularly maternal and child health and HIV/AIDS services, was estimated to improve implementation feasibility.
</p>
